Logo

Xenon's XEN1101 Meets its Primary Efficacy Endpoint in P-IIb X-TOLE Clinical Trial for the Treatment of Focal Epilepsy

Share this

Xenon's XEN1101 Meets its Primary Efficacy Endpoint in P-IIb X-TOLE Clinical Trial for the Treatment of Focal Epilepsy

Shots:

  • The P-IIb X-TOLE clinical trial evaluates the efficacy- safety- & tolerability of XEN1101 (25/20/10mg) vs PBO in 325 & 323 patients (in the safety & ITT population- respectively) with focal epilepsy
  • The trial met its 1EPs i.e.- patients achieved a median reduction in monthly focal seizure frequency from baseline (52.8%/46.4%/33.2% vs 18.2%)- and other measures included a ≥50% reduction in monthly focal seizure frequency from baseline (54.5%/43.1/28.3 vs 14.9). The therapy was generally well-tolerated
  • The therapy leads to treatment discontinuation due to AEs (15.8%/13.7%/ 2.2% vs 3.5)- higher incidence of TEAEs (85.1%/ 68.6%/ 67.4% vs 62.3)

  | Ref: Globe Newswire | Image: BioSpace

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions